Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal, or GI, diseases. Co.'s initial product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker, or P-CAB. P-CABs are medicines that block acid secretion in the stomach. Co. initiated two pivotal Phase 3 clinical trials for vonoprazan: one for the treatment of erosive gastroesophageal reflux disease, also known as erosive esophagitis; and a second for the treatment of Helicobacter pylori infection. The PHAT stock yearly return is shown above.
The yearly return on the PHAT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PHAT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|